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OBJECTIVES The purpose of this study was to investigate the utility of the new National Cholesterol
Education Program (NCEP) III guidelines in a group of young adults.
BACKGROUND These guidelines have been hailed as an improvement in their potential to identify individuals
at risk for coronary heart disease (CHD) complications. Compared with the NCEP II, the
new guidelines will increase the number of patients who qualify for medical management.
However, the effectiveness of these guidelines to identify young adults at risk for a cardiac
event is yet to be studied.
METHODS A retrospective review of clinical data from young adults (age 55 years for men and 65
years for women) hospitalized for acute myocardial infarction over a three-year period was
conducted. Patients with a history of CHD or CHD equivalent were excluded. Using the
NCEP III guidelines, we calculated a 10-year risk for coronary events on all patients.
RESULTS A total of 222 patients met criteria for inclusion. The mean age was 50 years and 25% were
women. Mean lipid levels were all within the normal range; however, rates of smoking and
obesity were high. When the 10-year risk of these patients was stratified by the number of risk
factors and low-density lipoprotein cholesterol level, only 25% met criteria to qualify for
pharmacotherapy. For women in this population, only 18% met criteria for treatment.
CONCLUSIONS The new guidelines offer multiple new features but have a tendency to underappreciate the
risk for disease in young adults. To improve performance in young adults, statistical
adjustments may be necessary. (J Am Coll Cardiol 2003;41:1475–9) © 2003 by the
American College of Cardiology Foundation
During the past four decades there has been a slow but
steady decline in age-adjusted mortality rates following
acute myocardial infarction (MI) (1). This improvement to
a large extent is attributed to newer treatment modalities for
acute-phase MI such as reperfusion strategies (2,3) and
secondary prevention strategies including beta-blockers
(4,5), aspirin (6), statins (7,8), and lifestyle changes (9,10).
However, the incident rate of acute coronary syndrome per
se has not slowed (1). Furthermore, primary prevention of
acute MI in the first place has been frustrating.
See page 1480
Today, the cornerstone of primary prevention of coronary
heart disease (CHD) in the U.S. is cholesterol management.
The National Cholesterol Education Program (NCEP) was
established as a national effort to educate professionals and
the public on the importance of cholesterol abnormalities
and CHD (11). The NCEP has created guidelines for
primary and secondary prevention of CHD. These guide-
lines are derived from evidence-based practice, supported by
several trials that demonstrate how treatment of high
cholesterol following acute MI improves outcomes (12,13).
Similarly, large trials have shown the benefits of prophylac-
tic treatment for primary prevention in certain high-risk
groups (14–16).
Recently, updated NCEP guidelines (17) were published
that include several new features designed to reclassify risk
based on the probability of an event in 10 years. In addition,
criteria were set for specific groups in the population, such
as for people with diabetes mellitus and others with non-
coronary manifestations of atherosclerotic disease. How-
ever, this new document has not been tested across different
population groups.
Previously we published a paper in which we found that
the NCEP II guidelines underestimated disease risk in
young adults (18). The purpose of this study was to
investigate the utility of the new NCEP III guidelines in a
group of young adults.
METHODS
Patient selection. This is a retrospective study of young
adults presenting with MI who were admitted to the
Coronary Care Unit at the Gundersen Lutheran Medical
Center in La Crosse, Wisconsin, with an MI in a three-year
period (January 1, 1998, to December 31, 2000). The
hospital catchment area and the demographic profile of the
community have been previously published (18). Age crite-
ria for young adults were defined as men age 55 years and
women age 65 years. Acute MI was defined as two of the
following: angina, electrocardiographic changes, or elevated
enzyme levels (creatine kinase, creatine kinase-myocardial
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band isoenzyme). Patients were excluded if they had a
history of CHD or diabetes (a CHD risk equivalent).
Data source and variables. Medical records of all eligible
patients were reviewed. The presence of traditional cardio-
vascular risk factors was noted. Body mass index (BMI) was
calculated for all patients and expressed as weight in
kilograms divided by the square of height in meters (kg/m2).
Overweight was defined as BMI 25 to 30 kg/m2 and obesity
was defined as BMI 30 kg/m2 for both men and women.
Cigarette smoking (yes or no) was ascertained for current
use, which was defined as chronic cigarette smoking up to
four weeks before acute MI. History of smoking was
established if the person reported smoking cessation for
longer than four weeks before the event. History of hyper-
tension was defined as systolic blood pressure140 mm Hg
or diastolic pressure of 90 mm Hg or current use of
antihypertensive medication. Family history of premature
CHD was defined as CHD in a first-degree relative at age
55 years and 65 years for men and women, respectively.
Hospital discharge records confirmed documentation of
MI. Per our clinical care pathway, all patients with acute
coronary syndrome have a lipid profile drawn within 12 h of
admission. If the patient has eaten in the past 12 h, the
patient receives nothing by mouth and a lipid profile is
drawn 12 h from the last meal.
Using the modified Framingham risk predictor model as
published in the new NCEP guidelines, we calculated a
10-year risk for coronary events on all patients. This was
done to see how well we would have identified these young
adults for prophylactic pharmacotherapy before their event.
Statistical analysis. The data were analyzed with SPSS
software (Version 9.0 for Windows, SPSS Inc., Chicago,
Illinois). Frequency distributions are reported and the Stu-
dent t test was used to determine differences between
genders.
RESULTS
General. In the calendar years 1998 through 2000, there
were a total of 284 admissions of young adults for acute MI
to our hospital. According to the new NCEP guidelines, 62
(18%) would have been classified as having CHD or a CHD
equivalent before their MI. The remaining 222 comprised
the population used in this study. Demographics are pro-
vided in Table 1. The mean patient age was 50  7 years.
There were 56 women (25%).
Risk factors. Table 1 provides a summary of the details of
the traditional risk factor distribution in this population.
The mean BMI was 30.0  5.8 kg/m2. Obesity was present
in 45% of the patients and an additional 37% were over-
weight. Thus, overweight and obese patients comprise 82%
of this population. Similarly, a history of smoking was high
and accounted for 75% of the population. As many as 60%
of patients were current smokers. As can be appreciated
from Table 1, the frequency rate for each categorical variable
was high. Under the new guidelines, major risk factors
include: smoking, hypertension, low high-density lipopro-
tein (HDL) cholesterol (40 mg/dl), family history of
CHD (CHD in male first-degree relative 55 years, in
female first-degree relative 65 years), and age (men 45
years, women55 years). In our population, multiple major
risk factors were present in 109 (49%) patients, whereas 113
(51%) had either no or only one risk factor.
Lipid levels. Table 2 displays the mean values of the
lipoprotein analysis. All 222 young adults had lipid profiles
drawn within 12 h of admission. As can be appreciated the
mean total cholesterol (190 mg/dl), low-density lipoprotein
(LDL) cholesterol (126 mg/dl), and HDL cholesterol (43
mg/dl) were all within the normal range. As a group, only
16% (n  32) had LDL cholesterol 160 mg/dl or higher.
The proportion of patients with LDL cholesterol 130
mg/dl was 58%, of whom 40% (n  51) of patients had
LDL cholesterol 100 mg/dl.
10-year calculated risk. The 10-year CHD risk in these
patients was stratified according to the number of major risk
factors present and LDL cholesterol level. The number of
people at high risk, that is, a 10-year risk 20% and two or
Abbreviations and Acronyms
BMI  body mass index
CHD  coronary heart disease
HDL  high-density lipoprotein
LDL  low-density lipoprotein
MI  myocardial infarction
NCEP  National Cholesterol Education Program
Table 1. Demographics and Risk Factor Profile
n  222




Overweight (BMI 25–29 kg/m2) 82 (37%)
Obese (BMI 30–34 kg/m2) 61 (28%)
Grossly obese (BMI 35 kg/m2) 37 (17%)
Smoker 133 (59.9%)
Ever smoked 167 (75%)
Hypertension 89 (40.1%)
Family history of premature CHD 94 (42.3%)
BMI  body mass index; CHD  coronary heart disease.





Total cholesterol 190.1  42.7 200
LDL cholesterol 125.7  38.6 130
HDL cholesterol
Men 41.7  14.9 40
Women 45.2  14.2
Triglycerides 145.0  77 150
HDL  high-density lipoprotein; LDL  low-density lipoprotein; NCEP 
National Cholesterol Education Program.
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more major risk factors, was 27 (12%), of whom only half
qualified for pharmacotherapy. Similarly, among the 39
patients with moderate risk (10% to 20%), only 21 qualified
for pharmacotherapy. In contrast, among low-risk groups,
very few qualified for therapy (6% of people with a 10-year
risk 10%, and 16% of people with no or one risk factor).
Remarkably, the majority (70%) of young adults were
stratified into these two lowest risk categories (n  156).
Table 3 provides a more complete illustration of the 10-year
calculated risk data. Overall, 166 patients (74.7%) did not
meet criteria to be identified as at sufficient risk to qualify
for pharmacotherapy. We repeated the analysis using non-
HDL cholesterol but the results did not change.
Gender differences. There were 56 (25%) women in this
study population. A comparison between genders for lipid
values was determined using the Student t test. The mean
total cholesterol was the same in both genders (190  44
mg/dl and 190  43 mg/dl in women and men, respective-
ly). The mean HDL cholesterol level was 46 14 mg/dl for
women and 42  15 mg/dl for men and not statistically
different (p  0.5). Women had a statistically lower mean
LDL cholesterol level (117 40 mg/dl vs. 129 38 mg/dl,
p  0.014). In contrast, the mean triglyceride level was
significantly higher in women than men (160  76 mg/dl
vs. 140  77 mg/dl, p  0.043). Whereas 35 men (21%)
had no known traditional cardiovascular risk factors, all of
the women had at least one risk factor, excluding high HDL
cholesterol. Counting high HDL cholesterol as a negative
risk factor, four women qualified as having no risk factors.
Also, using the Student t test, the mean number of major
risk factors present was higher in women than men (2.9 vs.
1.5 risk factors, p  0.001). In spite of the higher mean
number of risk factors present, no woman in this study had
a calculated risk of 20%. Only 5% of women in this study
had risk scores for probability of 10-year event between 10%
and 20%. Thus, the majority of women had a 10-year risk of
10%. Overall, 82% of women did not score high enough
to be identified for pharmacotherapy by the new guidelines,
compared with 59% of men.
DISCUSSION
Although mortality from CAD has declined steadily in the
past four decades, rates for acute coronary syndrome have
not slowed. Preventing the development of CHD and initial
MIs in the first place has been difficult. The new NCEP III
guidelines (17) for the management of dyslipidemia is the
best available document for primary prevention. This doc-
ument has several new features that make it an improvement
over previous guidelines. For primary prevention, physicians
are encouraged to calculate an individual’s absolute risk for
a cardiac event in 10 years. The LDL cholesterol targets and
goals of treatment are stratified according to the absolute
risk. A major advantage of the new guidelines is that many
people who did not qualify for aggressive medical manage-
ment using previous guidelines will be offered pharmaco-
therapy (19,20). However, the utility of these new guide-
lines has yet to be tested, particularly among young adults,
a population in which limitations of the previous guideline
have been recently documented (18,21).
In this study we applied the new guidelines in a group of
284 young adults with known acute MI. Our goal was to
determine each individual’s level of risk and whether or not
they would have met criteria for medical management if
they had presented to their physicians before the event. Of
the entire cohort, only 62 people (22%) had known CHD or
CHD equivalent and were excluded from this analysis
because they qualified for secondary prevention. The re-
maining 222 would have been candidates for primary
prevention if they had presented to their physicians before
the MI. As many as 75% did not qualify for medical
management. The prediction model as shown in Table 3 is
better for moderate- to high-risk patients, identifying 52%
of the people in this category. However, only 16% of the
entire cohort was in that group.
The infarct these patients had proved they were at high
risk. It seems reasonable to expect a predictive model to
detect more of these patients than it did. What are some of
the reasons that these guidelines do not perform well in
young adults? We did not study possible mechanistic
reasons, but do offer the following speculations. One reason
is that young adults have rarely been studied. With the
exception of a few studies such as Air Force/Texas Coronary
Atherosclerosis Prevention Study (AFCAPs/TexCAPs)
(14), young adults have been poorly represented in large
multicenter trials. Second, the clinical profile of young
adults with MI may be different from what is traditionally
believed (19,21). Premature CHD was considered rare
unless certain conditions, such as cocaine abuse, familial
Table 3. Ten-Year CHD Risk Profile
LDL Cholesterol (mg/dl) Total
<100 100–129 130–159 >160 % Cohort
2 risk factors 10-year risk 20% 2 (1%) 11 (5%) 7 (3%) 7 (3%) 27 (12%)
2 risk factors 10-year risk 10%–20% 6 (3%) 12 (5%) 13 (6%) 8 (4%) 39 (18%)
2 risk factors 10-year risk 10% 12 (5%) 22 (10%) 9 (4%) 3 (1%) 45 (20%)
0–1 risk factor 31 (14%) 33 (15%) 28 (13%) 18 (8%) 110 (50%)
Total (% cohort) 51 (23%) 78 (35%) 57 (29%) 36 (16%)
Bold type indicates those patients not qualifying for medical management.
CHD  coronary heart disease; LDL  low-density lipoprotein.
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hyperlipidemia, or diabetes were present. In our experience,
25% of all acute coronary syndrome hospital admissions
were in adults 50 years or younger (18). Moreover, this
young adult population with CHD is characterized by a
high prevalence of individual categorical risk factors, but as
many as 50% do not have clusters (two or more) of risk
factors. Moreover, a significant number of these young
adults have LDL cholesterol below 100 mg/dl (22).
As can be viewed in Table 1, the frequency rate of
smoking is exceptionally high. In the new guidelines,
smoking is stratified according to age with higher scores
assigned to younger ages. For instance, a 20- to 29-year-old
smoker is assigned a score of 8, whereas a 50- to 59-year-old
smoker is given a score of 3. This system of scoring fails to
account for the intensity of exposure (duration and number
of packs) to tobacco. In the risk assessment of young adults,
the intensity of smoking (defined as number of pack years)
may be a better basis for stratification than age.
In addition, overweight/obesity as a traditional risk factor
was present in 82% of these young adults. In the new
guidelines, obesity is not directly scored in risk assessment.
The effect of obesity may be accounted for in the role it
plays in metabolic syndrome and hypercholesterolemia.
However, in a population such as our subjects with high
frequency rates of overweight, the full impact of obesity may
be unappreciated. The effect of obesity on CHD may need
to be re-evaluated in the current era where obesity rates are
increasing in all segments of the population.
It may be that (for young adults) long and intense
exposure to certain major categorical risk factors may be
more detrimental than exposure to multiple marginal risk
factors. This may be true for risk factors such as smoking
and obesity, both of which are usually acquired early and
have a high probability of being maintained.
A distinguishing feature in the clinical profile of our
adults is that the vast majority did not have high total
cholesterol or LDL cholesterol levels. As many as 58% had
LDL cholesterol levels of 130 mg/dl or less, and 50% do not
have multiple risk factors. These factors may contribute to
the poor performance of current guidelines for prevention of
premature CHD.
Does this mean that cholesterol is not important in young
adults? We interpret our results to mean that optimal
cholesterol levels do not imply freedom from CHD in
young adults with other modifiable risk factors. The mes-
sage is that we should target all modifiable risk factors with
the same intensity given to cholesterol.
CONCLUSIONS
The Adult Treatment Panel III guidelines incorporate
several new features that may potentially improve primary
prevention of premature CHD. However, for physicians to
feel comfortable with these, they may need to be validated
across several population groups. We found that many
young adults presenting with MI do not have multiple risk
factors, and few (16%) have moderately high LDL choles-
terol levels. By contrast, the rates of categorical risk factors
including overweight/obesity, smoking, and hypertension
are high. Young women presenting with MI generally have
a higher likelihood of multiple risk factors. In spite of this,
the new guidelines failed to appreciate the risk for under-
lying disease in women. More studies are needed to validate
the new guidelines in young adults and to determine the
necessary statistical adjustments to improve performance in
young adults at risk for MI.
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